|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03759 PHARMARON
Nominal 
27.760 -0.880 (-3.073%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 6,440,951 | 14.925% | 12,275,775 | 11,537,996 | 10,266,288 | 7,443,770 |
| Cost of Sales | (4,268,750) | 13.639% | (8,126,520) | (7,443,176) | (6,517,012) | (4,771,726) |
| Gross Profit | 2,172,201 | 17.540% | 4,149,255 | 4,094,820 | 3,749,276 | 2,672,044 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (37,143) | 61.914% | (116,486) | (35,825) | (21,157) | (10,269) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (32,657) | 7.758% | (123,256) | (2,084) | (33,851) | 71,845 | |
| Profit / (Loss) before Taxation | 812,756 | -33.753% | 2,091,263 | 1,837,887 | 1,666,391 | 1,910,996 | |
| Taxation | (160,126) | 11.272% | (377,104) | (256,106) | (314,254) | (290,919) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 48,766 | 60.114% | 79,192 | 19,315 | 22,467 | 40,952 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 701,396 | -37.004% | 1,793,351 | 1,601,096 | 1,374,604 | 1,661,029 | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 76,709 | -12.205% | 170,087 | 148,649 | 132,099 | 18,666 |
| Depreciation & Amortisation | 609,426 | 9.843% | 1,145,412 | 1,008,588 | 766,063 | 577,673 |
| Directors' Emoluments | -- | -- | 6,903 | 6,916 | 6,955 | 21,653 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 39.840 | -36.581% | 101.330 | 90.330 | 77.500 | 93.253 |
| DPS (cts) | 0.000 | -- | 20.000 | 20.000 | 20.000 | 20.000 |
| Dividend Payout Ratio (%) | -- | -- | 19.737% | 22.141% | 25.806% | 21.447% |
| Cash flow per share ($) | -- | -- | 1.456 | 1.554 | 1.209 | 1.156 |
| NBV per share ($) | 8.056 | -- | 7.690 | 6.917 | 5.793 | 5.558 |
| Remarks: | Real time quote last updated: 18/09/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 701,396 |
| %Change | -37.004% |
| EPS / (LPS) | RMB 0.398 |
| NBV Per Share (¥) | RMB 8.056 |